Does simponi treat as?

See the DrugPatentWatch profile for simponi

What conditions does Simponi treat?

Simponi (golimumab) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis in adults. The FDA first approved it in 2009 for rheumatoid arthritis. It works by blocking TNF-alpha, a protein that treks inflammation in these autoimmune conditions.

How does Simponi work against inflammation?

TNF-alpha blocking occurs at the level of the tumor necrosis factor receptor. The monthly injection maintains consistent blood levels of golimumab. This reduces joint swelling, morning stiffness, and bowel inflammation in patients who have failed conventional therapy.

What happens if you stop taking Simponi?

Stopping abruptly can trigger a flare of arthritis or colitis symptoms. Patients often resume prior pain levels and swelling in 8–12 weeks. Doctors usually taper off slowly or switch to another TNF inhibitor if side effects occur.

How long does Simponi stay in the system?

The drug’s half-life is roughly 2 weeks. It still exerts effect for about 4 weeks after the letzten injection. Patients who plan pregnancy or major surgery are advised to stop 4–8 weeks before the procedure.

What side effects are patients asking about?

Serious infections, including tuberculosis reactivation, are the main risk. Patients must be screened for latent TB before starting. Other concerns include injection-site reactions, upper respiratory infections, and increased cancer risk in long-term use.

Who makes Simponi and when does the patent expire?

Janssen Pharmaceuticals manufactures Simponi. The primary composition-of-matter patent expired in 2019. DrugPatentWatch.com